help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints, Permissions and Rights
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caballero, A. E.
Right arrow Articles by Rull, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caballero, A. E.
Right arrow Articles by Rull, J. A.
The Journal of Clinical Endocrinology & Metabolism Vol. 89, No. 8 3943-3948
Copyright © 2004 by The Endocrine Society

The Differential Effects of Metformin on Markers of Endothelial Activation and Inflammation in Subjects with Impaired Glucose Tolerance: A Placebo-Controlled, Randomized Clinical Trial

A. Enrique Caballero, Adriano Delgado, Carlos A. Aguilar-Salinas, Alberto Naranjo Herrera, Jose Luis Castillo, Tatiana Cabrera, Francisco J. Gomez-Perez and Juan A. Rull

Clinical Research Center (A.E.C.), Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts 02215; and Departments of Endocrinology and Metabolism (A.D., C.A.A.-S., A.N.H., J.L.C., F.J.G.-P.), Radiology (T.C.), and Medicine (J.A.R.), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan 14000, Mexico City, Mexico

Address all correspondence and requests for reprints to: Carlos A. Aguilar-Salinas, M.D., Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga Number 15, Tlalpan 14000, Mexico City, Mexico. E-mail: caguilarsalinas{at}yahoo.com.

The effect of metformin (1000 mg twice a day) on markers of endothelial activation, inflammation, and coagulation was investigated in subjects with impaired glucose tolerance (IGT) in a 16-wk, randomized, placebo-controlled, double-blind study. Soluble intercellular adhesion molecule, soluble vascular cell adhesion molecule, C-reactive protein, TNF{alpha}, von Willebrand factor, and tissue plasminogen activator were measured at baseline and at the end of the trial. Subjects with IGT (n = 55, 14 males and 41 females), aged 48.4 ± 9.6 yr with a body mass index of 31.4 ± 5.6 kg/m2, were studied. All participants followed a 1-month stabilization period in their diet and physical activity. Afterward, 29 subjects were assigned to the treatment group and 26 to the control group. A significant reduction in weight, fasting plasma glucose, soluble intercellular adhesion molecule (306 ± 75 vs. 268 ± 61 ng/ml, P = 0.029), soluble vascular cell adhesion molecule (595 ± 114 vs. 508 ± 126 ng/ml, P = 0.006), and von Willebrand factor (124 ± 34 vs. 94 ± 34%, P = 0.001) was seen in the treatment group, whereas tissue plasminogen activator, TNF{alpha}, and C-reactive protein levels did not change. No change was seen in the control group. Thus, metformin improves the plasma levels of some markers of endothelial activation and coagulation in subjects with IGT, whereas it has no effect on markers of inflammation.

This work was supported by a grant from Silanes Laboratories through FunSalud, a nonprofit health care organization in Mexico.

Abbreviations: A1c, Hemoglobin A1C; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; FPG, fasting plasma glucose; HDL, high-density lipoprotein; HOMA, homeostasis model of assessment; IGT, impaired glucose tolerance; IR, insulin resistance; LDL, low-density lipoprotein; PAI-1, plasminogen-activator inhibitor 1; sICAM, soluble intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion molecule; tPA, tissue plasminogen activator; vWF, von Willebrand factor.




This article has been cited by other articles:


Home page
 JCOHome page
S. Jiralerspong and A. M. Gonzalez-Angulo
Reply to T. Grenader et al
J. Clin. Oncol., December 10, 2009; 27(35): e260 - e260.
[Full Text] [PDF]

Home page
 JAMAHome page
A. D. Pradhan, B. M. Everett, N. R. Cook, N. Rifai, and P. M Ridker
Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes: The LANCET Randomized Trial
JAMA, September 16, 2009; 302(11): 1186 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. B. Goldberg
Cytokine and Cytokine-Like Inflammation Markers, Endothelial Dysfunction, and Imbalanced Coagulation in Development of Diabetes and Its Complications
J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3171 - 3182.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Nath, M. Khan, M. K. Paintlia, M. N. Hoda, and S. Giri
Metformin Attenuated the Autoimmune Disease of the Central Nervous System in Animal Models of Multiple Sclerosis
J. Immunol., June 15, 2009; 182(12): 8005 - 8014.
[Abstract] [Full Text] [PDF]

Home page
 cfpHome page
M. Lilly and M. Godwin
Treating prediabetes with metformin: Systematic review and meta-analysis
Can Fam Physician, April 1, 2009; 55(4): 363 - 369.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. Kooy, J. de Jager, P. Lehert, D. Bets, M. G. Wulffele, A. J. M. Donker, and C. D. A. Stehouwer
Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus
Arch Intern Med, March 23, 2009; 169(6): 616 - 625.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
P. Dandona
Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein
Mayo Clin. Proc., March 1, 2008; 83(3): 333 - 342.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
G. Perriello, S. Pampanelli, P. Brunetti, C. D. Pietro, and S. Mariz
Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes
Diabetes and Vascular Disease Research, September 1, 2007; 4(3): 226 - 230.
[Abstract] [PDF]

Home page
 Hum ReprodHome page
T. Persico, V. Savasi, E. Ferrazzi, M. Oneta, A.E. Semprini, and G. Simoni
Detection of human immunodeficiency virus-1 RNA and DNA by extractive and in situ PCR in unprocessed semen and seminal fractions isolated by semen-washing procedure
Hum. Reprod., June 1, 2006; 21(6): 1525 - 1530.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
E. Diamanti-Kandarakis, T. Paterakis, K. Alexandraki, C. Piperi, A. Aessopos, I. Katsikis, N. Katsilambros, G. Kreatsas, and D. Panidis
Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin
Hum. Reprod., June 1, 2006; 21(6): 1426 - 1431.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
Y. Hattori, K. Suzuki, S. Hattori, and K. Kasai
Metformin Inhibits Cytokine-Induced Nuclear Factor {kappa}B Activation Via AMP-Activated Protein Kinase Activation in Vascular Endothelial Cells
Hypertension, June 1, 2006; 47(6): 1183 - 1188.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
K. Isoda, J. L. Young, A. Zirlik, L. A. MacFarlane, N. Tsuboi, N. Gerdes, U. Schonbeck, and P. Libby
Metformin Inhibits Proinflammatory Responses and Nuclear Factor-{kappa}B in Human Vascular Wall Cells
Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 611 - 617.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society